Myriad Genetics Inc
MYGN7.980USD
-0.060-0.75%
Horário de mercado （ET）Cotações atrasadas em 15 min
742.94MValor de mercado
PerdaP/L TTM
Mais detalhes de Myriad Genetics Inc Empresa
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Informações de Myriad Genetics Inc
Código da empresaMYGN
Nome da EmpresaMyriad Genetics Inc
Data de listagemOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Número de funcionários2700
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 06
Endereço322 North 2200 West
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84116
Telefone18015843600
Sitehttps://myriad.com/
Código da empresaMYGN
Data de listagemOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Executivos da empresa Myriad Genetics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Por RegiãoUSD
Nome
Receita
Proporção
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Distribuição de ações
Atualizado em: qua, 8 de out
Atualizado em: qua, 8 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Outro
61.70%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Outro
61.70%
Tipos de investidores
Investidores
Proporção
Investment Advisor
37.21%
Hedge Fund
27.56%
Investment Advisor/Hedge Fund
25.31%
Research Firm
6.02%
Individual Investor
3.32%
Pension Fund
1.88%
Bank and Trust
0.41%
Venture Capital
0.31%
Family Office
0.08%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
515
91.89M
98.76%
-9.78M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.07M
2.23%
-139.99K
-6.33%
Jun 30, 2025
Qube Research & Technologies Ltd
2.05M
2.21%
+633.44K
+44.67%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
WisdomTree BioRevolution Fund
0.81%
Federated Hermes MDT Small Cap Core ETF
0.74%
Global X Genomics & Biotechnology ETF
0.74%
Invesco NASDAQ Future Gen 200 ETF
0.55%
Invesco S&P SmallCap Health Care ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.26%
Strategas Global Policy Opportunities ETF
0.23%
SPDR S&P Biotech ETF
0.21%
Vanguard US Quality Factor ETF
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
Ver Mais
WisdomTree BioRevolution Fund
Proporção0.81%
Federated Hermes MDT Small Cap Core ETF
Proporção0.74%
Global X Genomics & Biotechnology ETF
Proporção0.74%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.55%
Invesco S&P SmallCap Health Care ETF
Proporção0.43%
Inspire Small/Mid Cap ESG ETF
Proporção0.26%
Strategas Global Policy Opportunities ETF
Proporção0.23%
SPDR S&P Biotech ETF
Proporção0.21%
Vanguard US Quality Factor ETF
Proporção0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.12%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
